Lead compound for potential treatment of acute kidney injury identified
A new 6-chromanol-derived compound named SUL-138 has shown promise in animal models at treating acute kidney injury.
List view / Grid view
A new 6-chromanol-derived compound named SUL-138 has shown promise in animal models at treating acute kidney injury.
Scientists used a new screen to identify FAM72A as a cause of mutagenesis that affects antibody development in COVID-19 and cancer.
The new high-throughput screening method identified nine lead molecules for rhodopsin dimerisation that may lead to next-generation medicines.
A new study prevented the growth of metastatic tumours in mice by forcing cancer cells into a dormant state, pointing to novel treatments.
Scientists unveil the role of KCNQ2/3 using a functional screen of 40 native US plants and identify nine extracts that could treat diarrhoea.
Ncardia has formed a strategic partnership with Kiniciti to build GMP capabilities to support iPSC cell therapy platforms and human cell-based in vitro discovery services.
Following Drug Target Review's webinar supported by Eurofins, speaker Dr Verena Albert answers the questions posed by the audience during the live event.
27 October 2021 | By Takara Bio
Watch this free one-hour session to discover how refined cell atlases can provide comprehensive roadmaps for health and disease.
This whitepaper overviews phenotypic and functional characterisation of CAR-T cells with advanced flow cytometry and live-cell analysis.
Scientists have identified potential cancer drugs to treat pulmonary hypertension using experimental and computational approaches.
The antimicrobial hygromycin A was shown to clear Lyme disease in mice, representing a promising therapeutic against the disease.
A new antiviral has shown promise against the dengue virus in mice and has the potential to be used as a preventative measure.
Researchers are identifying molecules that interact with neurolysin, a peptidase that helps protect the brain against stroke.
Landmark pre-clinical studies to investigate whether psychedelic derivatives can reduce alcohol consumption have been initiated.
Targets for drug discovery can be identified with AI but require validation in vitro. Here’s how this can be done, using hiPSC technology.